ReceptoPharm  
Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

Newsroom

Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain
October 14, 2009

Nutra Pharma’s over-the-counter treatment for moderate to severe chronic pain, Cobroxin, is now available for sale online at Cobroxin.com. The Company plans to announce additional retail partnerships as it moves through the fourth quarter of 2009 and into the first quarter of 2010.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.

Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

  • All Natural
  • Non-Addictive
  • Non-Narcotic
  • Non-Opiate
  • More Potent than Morphine
  • Long Lasting

“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.

In August, Nutra Pharma announced that it had granted XenaCare Holdings an exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the availability of Cobroxin online at Cobroxin.com should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC